Drug Profile
Research programme: Alzheimer's disease therapeutics - KeyNeurotek AG
Alternative Names: SRN 003 Tau research programme; SRN-003-556Latest Information Update: 26 Feb 2008
Price :
$50
*
At a glance
- Originator KeyNeurotek AG
- Developer KeyNeurotek Pharmaceuticals AG
- Class Carbazoles
- Mechanism of Action Mitogen-activated protein kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 16 Jul 2004 Preclinical trials in Alzheimer's disease in Germany (unspecified route)